BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 15471221)

  • 1. Interaction between clonal plasma cells and the immune system in plasma cell dyscrasias.
    Perez-Andres M; Almeida J; Martin-Ayuso M; Moro MJ; Garcia-Marcos MA; Moreno I; Dominguez M; Galende J; Heras N; Gonzalez MI; San Miguel JF; Orfao A;
    J Biol Regul Homeost Agents; 2004; 18(2):161-5. PubMed ID: 15471221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clonal plasma cells from monoclonal gammopathy of undetermined significance, multiple myeloma and plasma cell leukemia show different expression profiles of molecules involved in the interaction with the immunological bone marrow microenvironment.
    Pérez-Andrés M; Almeida J; Martín-Ayuso M; Moro MJ; Martín-Nuñez G; Galende J; Borrego D; Rodríguez MJ; Ortega F; Hernandez J; Moreno I; Domínguez M; Mateo G; San Miguel JF; Orfao A; ;
    Leukemia; 2005 Mar; 19(3):449-55. PubMed ID: 15674420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of bone marrow T cells in monoclonal gammopathy of undetermined significance, multiple myeloma, and plasma cell leukemia demonstrates increased infiltration by cytotoxic/Th1 T cells demonstrating a squed TCR-Vbeta repertoire.
    Pérez-Andres M; Almeida J; Martin-Ayuso M; Moro MJ; Martin-Nuñez G; Galende J; Hernandez J; Mateo G; San Miguel JF; Orfao A; ;
    Cancer; 2006 Mar; 106(6):1296-305. PubMed ID: 16475149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MICA expressed by multiple myeloma and monoclonal gammopathy of undetermined significance plasma cells Costimulates pamidronate-activated gammadelta lymphocytes.
    Girlanda S; Fortis C; Belloni D; Ferrero E; Ticozzi P; Sciorati C; Tresoldi M; Vicari A; Spies T; Groh V; Caligaris-Cappio F; Ferrarini M
    Cancer Res; 2005 Aug; 65(16):7502-8. PubMed ID: 16103105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Telomerase activity in plasma cell dyscrasias.
    Xu D; Zheng C; Bergenbrant S; Holm G; Björkholm M; Yi Q; Gruber A
    Br J Cancer; 2001 Mar; 84(5):621-5. PubMed ID: 11237381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma.
    Ocqueteau M; Orfao A; Almeida J; Bladé J; González M; García-Sanz R; López-Berges C; Moro MJ; Hernández J; Escribano L; Caballero D; Rozman M; San Miguel JF
    Am J Pathol; 1998 Jun; 152(6):1655-65. PubMed ID: 9626070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathogenetic relation between monoclonal gammopathies of undetermined significance and multiple myeloma.
    Greipp PR; Lust JA
    Stem Cells; 1995 Aug; 13 Suppl 2():10-21. PubMed ID: 8520496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunophenotypic and DNA content characteristics of plasma cells in multiple myeloma and monoclonal gammopathy of undetermined significance.
    Almeida J; Orfao A; Mateo G; Ocqueteau M; García-Sanz R; Moro MJ; Hernandez J; Ortega F; Borrego D; Barez A; Mejido M; San Miguel JF
    Pathol Biol (Paris); 1999 Feb; 47(2):119-27. PubMed ID: 10192879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differentiation of monoclonal gammopathy of undetermined significance and multiple myeloma using flow cytometric characteristics of plasma cells.
    Sezer O; Heider U; Zavrski I; Possinger K
    Haematologica; 2001 Aug; 86(8):837-43. PubMed ID: 11522540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neural cell adhesion molecule expression in plasma cells in bone marrow biopsies and aspirates allows discrimination between multiple myeloma, monoclonal gammopathy of uncertain significance and polyclonal plasmacytosis.
    Martín P; Santón A; Bellas C
    Histopathology; 2004 Apr; 44(4):375-80. PubMed ID: 15049904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myeloma.
    Paiva B; Pérez-Andrés M; Vídriales MB; Almeida J; de las Heras N; Mateos MV; López-Corral L; Gutiérrez NC; Blanco J; Oriol A; Hernández MT; de Arriba F; de Coca AG; Terol MJ; de la Rubia J; González Y; Martín A; Sureda A; Schmidt-Hieber M; Schmitz A; Johnsen HE; Lahuerta JJ; Bladé J; San-Miguel JF; Orfao A; ;
    Leukemia; 2011 Apr; 25(4):697-706. PubMed ID: 21252988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD44v6, a target for novel antibody treatment approaches, is frequently expressed in multiple myeloma and associated with deletion of chromosome arm 13q.
    Liebisch P; Eppinger S; Schöpflin C; Stehle G; Munzert G; Döhner H; Schmid M
    Haematologica; 2005 Apr; 90(4):489-93. PubMed ID: 15820944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dysregulation of CD47 and the ligands thrombospondin 1 and 2 in multiple myeloma.
    Rendtlew Danielsen JM; Knudsen LM; Dahl IM; Lodahl M; Rasmussen T
    Br J Haematol; 2007 Sep; 138(6):756-60. PubMed ID: 17760807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kappa/lambda ratio on peripheral blood lymphocytes and bone marrow plasma cell labeling index in monoclonal gammopathies.
    Büchi G; Girotto M; Veglio M; Clerico M; Gario S; Termine G; Autino R
    Haematologica; 1990; 75(2):132-6. PubMed ID: 2113507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance.
    Kumar S; Rajkumar SV; Kyle RA; Lacy MQ; Dispenzieri A; Fonseca R; Lust JA; Gertz MA; Greipp PR; Witzig TE
    J Clin Oncol; 2005 Aug; 23(24):5668-74. PubMed ID: 16110026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone-marrow immunophenotypic analysis allows the identification of high risk of progression and immune condition-related monoclonal gammopathy of undetermined significance.
    Jerez A; Ortuño FJ; Osma Mdel M; Español I; González AD; Roldán V; de Arriba F; Vicente V
    Ann Med; 2009; 41(7):547-58. PubMed ID: 19634064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD229 is expressed on the surface of plasma cells carrying an aberrant phenotype and chemotherapy-resistant precursor cells in multiple myeloma.
    Yousef S; Kovacsovics-Bankowski M; Salama ME; Bhardwaj N; Steinbach M; Langemo A; Kovacsovics T; Marvin J; Binder M; Panse J; Kröger N; Luetkens T; Atanackovic D
    Hum Vaccin Immunother; 2015; 11(7):1606-11. PubMed ID: 26001047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma cell antigens in human multiple myeloma.
    Mackenzie MR; Paglieroni TG
    J Lab Clin Med; 1977 May; 89(5):1009-17. PubMed ID: 67161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD19 and immunophenotype of bone marrow plasma cells in monoclonal gammopathy of undetermined significance.
    Zandecki M; Facon T; Bernardi F; Izydorczyk V; Dupond L; François M; Reade R; Iaru T; Bauters F; Cosson A
    J Clin Pathol; 1995 Jun; 48(6):548-52. PubMed ID: 7545187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders.
    Paiva B; Almeida J; Pérez-Andrés M; Mateo G; López A; Rasillo A; Vídriales MB; López-Berges MC; Miguel JF; Orfao A
    Cytometry B Clin Cytom; 2010 Jul; 78(4):239-52. PubMed ID: 20155853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.